Editas Medicine, Inc.

NasdaqGS:EDIT Rapporto sulle azioni

Cap. di mercato: US$239.3m

Editas Medicine Performance dei guadagni passati

Il passato criteri di controllo 0/6

Editas Medicine's earnings have been declining at an average annual rate of -11.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 4.5% per year.

Informazioni chiave

-11.1%

Tasso di crescita degli utili

-2.1%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.0%
Tasso di crescita dei ricavi4.5%
Rendimento del capitale proprio-83.4%
Margine netto-288.6%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23
Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15
New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25
Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Ripartizione dei ricavi e delle spese

Come Editas Medicine guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqGS:EDIT Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 2467-1936735
31 Mar 2469-166660
31 Dec 2378-153700
30 Sep 2325-1957363
30 Jun 2319-2067463
31 Mar 2323-219740
31 Dec 2220-220710
30 Sep 2226-201690
30 Jun 2232-184690
31 Mar 2226-186740
31 Dec 2126-193760
30 Sep 2124-214750
30 Jun 2181-167790
31 Mar 2192-135710
31 Dec 2091-116680
30 Sep 2092-91690
30 Jun 2033-132650
31 Mar 2024-142650
31 Dec 1921-134650
30 Sep 1914-121610
30 Jun 1925-103580
31 Mar 1930-108580
31 Dec 1832-110550
30 Sep 1829-121560
30 Jun 1821-132550
31 Mar 1817-120520
31 Dec 1714-120510
30 Sep 1711-124500
30 Jun 176-118490
31 Mar 176-111490
31 Dec 166-97460
30 Sep 166-71410
30 Jun 166-57330
31 Mar 162-86250
31 Dec 152-73180
30 Sep 151-66140
30 Jun 150-62110
31 Mar 150-1790
31 Dec 140-1480

Guadagni di qualità: EDIT is currently unprofitable.

Margine di profitto in crescita: EDIT is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: EDIT is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.

Accelerare la crescita: Unable to compare EDIT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: EDIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendimento del capitale proprio

ROE elevato: EDIT has a negative Return on Equity (-83.38%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate